Thymosin Alpha-1 Biohacker and Longevity Stack Protocol: Dosing, Cycling, and Monitoring

What Is Thymosin Alpha-1 and Why Do Longevity Researchers Care About It?

Thymosin Alpha-1 is an endogenous peptide originally isolated from thymosin fraction 5 of bovine thymus tissue by Allan Goldstein's team in 1977. The thymus gland produces TA-1 naturally, but output drops sharply after puberty and continues declining with age. By age 60, circulating thymosin levels may be 50 to 80 percent lower than in young adulthood, a pattern that tracks closely with the age-related contraction of T-cell diversity and innate immune competence observed in immunosenescence research [1].

The Immunosenescence Connection

Immunosenescence, the gradual deterioration of immune architecture with age, is now recognized as a driver of all-cause morbidity. A 2021 review in Immunity and Ageing documented that thymic involution precedes measurable declines in naive T-cell output and correlates with increased susceptibility to viral illness, reduced vaccine responsiveness, and higher cancer incidence [2]. TA-1 partially addresses this deficit by acting on dendritic cells and natural killer cells upstream of the adaptive immune cascade.

Mechanistic Actions Relevant to Longevity

TA-1 binds Toll-like receptor 9 (TLR9) and activates downstream NF-kB and MAPK pathways. This drives interferon-alpha secretion, upregulates MHC class I antigen presentation, and skews the Th1/Th2 balance toward a Th1-dominant, pro-cytotoxic state [3]. For longevity-focused users, the rationale is straightforward: a Th1-biased immune environment is better at clearing senescent cells, controlling latent viral reactivation (EBV, CMV, HSV), and mounting initial antitumor surveillance. Aging disproportionately shifts the immune system toward Th2 dominance and chronic low-grade inflammation, a phenotype sometimes called "inflammaging."

Clinical Evidence Supporting TA-1 Use

The evidence base for TA-1 is broader than for most peptides discussed in biohacking circles. It should not be confused with anecdote-only compounds.

Phase III RCT Data in Chronic Hepatitis B

The largest randomized controlled trial evidence comes from chronic hepatitis B. A Phase III trial published in Hepatology (N=161) showed that TA-1 1.6 mg twice weekly for 6 months produced a sustained virologic response rate of 28 percent versus 8 percent in controls, with the combination arm (TA-1 plus interferon-alpha) reaching 40 percent [4]. Daily dosing in that trial did not outperform twice-weekly administration, a pharmacokinetic finding that informs modern biohacker scheduling directly.

Sepsis and Critical Illness Studies

A 2013 RCT in Critical Care Medicine (N=361) enrolled patients with severe sepsis and found that TA-1 significantly reduced 28-day mortality compared to placebo (26.0% vs 35.2%, P<0.05) by restoring HLA-DR expression on monocytes, a biomarker of immune paralysis [5]. This is not a longevity-use dataset, but it demonstrates TA-1's capacity to reverse measurable immune dysfunction in a controlled clinical setting.

Cancer Adjuvant Data

A Phase II trial in stage IV melanoma (N=56) combined TA-1 with dacarbazine and found a median overall survival of 14.7 months versus 9.2 months for chemotherapy alone [6]. The mechanism proposed was TA-1-driven restoration of CD8+ T-cell infiltration into tumor microenvironments. For longevity users, the relevance is not chemotherapy combination; it is the CD8+ activation phenotype TA-1 generates at physiologic doses.

The Biohacker Protocol: Dose, Route, and Schedule

The protocol below synthesizes hepatitis-B RCT pharmacokinetics, the sepsis dosing literature, and practitioner-level observational experience reported in peer-reviewed compounding pharmacy and integrative medicine contexts. No RCT has enrolled healthy adults purely for longevity optimization. Treat this framework as evidence-informed, not evidence-proven.

Standard Induction Phase (Weeks 1 to 12)

Dose: 1.5 mg per injection. This mirrors the commercially available vial size of Zadaxin (thymalfasin), the approved TA-1 formulation used in 35+ countries, and aligns with the hepatitis B RCT dosing that produced the most consistent immune outcomes [4].

Route: Subcutaneous injection only. TA-1 has a very short plasma half-life of approximately 2 hours when given intravenously, but subcutaneous administration extends effective tissue exposure to 10 to 12 hours via slower absorption. Use a 29 to 31-gauge, 0.5-inch insulin syringe. Rotate injection sites among the abdomen, lateral thigh, and posterior upper arm.

Frequency: Two to three times per week, spaced at least 48 hours apart. The Monday-Wednesday-Friday schedule is the most common in community practice. The hepatitis B trial used Monday-Thursday dosing (twice weekly) with equivalent immunological outcomes to three-times-weekly administration, suggesting receptor saturation may limit any benefit from higher frequency [4].

Reconstitution: Lyophilized TA-1 powder is typically reconstituted in bacteriostatic water (0.9% benzyl alcohol saline). Add 1 mL of bacteriostatic water per 1.5 mg vial for a 1.5 mg/mL working concentration. Store reconstituted peptide at 2 to 8 degrees Celsius and discard after 28 days.

Maintenance Phase (After Week 12)

After completing the 12-week induction, most longevity-focused practitioners shift to a quarterly maintenance model: one 6-week pulse per quarter, at 1.5 mg twice weekly. This totals roughly 18 mg per quarter, or 72 mg annually. The rationale is that thymic peptide levels respond to pulsatile stimulation rather than continuous dosing, similar to the LH-RH pulse dynamics seen in gonadotropin biology.

Cycling Off

Take at minimum 8 weeks completely off between active cycles. Because TA-1 upregulates T-cell activity, sustained continuous dosing could theoretically lower the threshold for autoimmune flares in genetically susceptible individuals, though no published case series has confirmed this risk. Eight weeks off allows immunological baselines to re-establish before monitoring labs are repeated.

Stacking TA-1 With Other Longevity Compounds

Most biohacker protocols do not use TA-1 in isolation. Below are the most commonly combined compounds and the rationale for each pairing.

BPC-157 (Body Protective Compound-157)

BPC-157 is a 15-amino-acid gastric peptide with documented anti-inflammatory and angiogenic properties in rodent models [7]. Pairing it with TA-1 follows a logical division of labor: BPC-157 targets tissue repair and gut-barrier integrity while TA-1 handles systemic immune calibration. There is no human RCT for BPC-157 at the time of writing. Doses used in community protocols are 250 to 500 mcg subcutaneously once daily, separate from TA-1 injections.

Epithalon (Epitalon)

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal gland extract. It has been studied by Vladimir Khavinson's group for effects on telomere elongation and circadian gene expression in aged animals and small human cohorts [8]. The combination with TA-1 targets two separate aging vectors: thymic immune decline (TA-1) and epigenetic/telomeric aging (Epithalon). Typical community dosing is 5 to 10 mg Epithalon per day for 10 consecutive days, run as a separate pulse during the TA-1 off-weeks.

Low-Dose Naltrexone (LDN)

LDN (1.5 to 4.5 mg nightly, oral) is the most evidence-supported immune-modulating co-treatment in this class. A 2018 pilot RCT published in Annals of Rheumatic Disease showed LDN reduced inflammatory cytokine burden in Crohn's disease [9]. Its proposed mechanism, transient mu-opioid receptor blockade driving endogenous opioid upregulation and subsequent immune recalibration, is orthogonal to TA-1's TLR9-mediated pathway. Using both together may address immune dysfunction through complementary, non-overlapping mechanisms.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of thymosin beta-4, sharing the thymosin family lineage but acting primarily on actin polymerization and tissue repair rather than adaptive immunity [10]. It is commonly stacked with TA-1 in injury-recovery contexts but its longevity rationale is less defined than BPC-157.

Monitoring Labs: What to Check and When

Running TA-1 without baseline labs is a clinical error. The immune system is not a one-directional lever, and tracking objective markers is the only way to distinguish a genuine response from placebo effect or subclinical adverse signaling.

Baseline Panel (Before First Injection)

Run these labs within two weeks before starting TA-1:

• Complete blood count with five-part differential (absolute lymphocyte, neutrophil, monocyte counts)
• CD3+, CD4+, CD8+ T-cell absolute counts and CD4/CD8 ratio
• NK cell activity assay (CD16+/CD56+ percentage)
• High-sensitivity CRP (hsCRP)
• IL-6 (interleukin-6, serum)
• ANA (antinuclear antibody screen, to rule out pre-existing autoimmunity)
• Comprehensive metabolic panel
• Thyroid panel (TSH, free T3, free T4) because TA-1 can influence thyroid hormone metabolism via immune-thyroid crosstalk [1]

Mid-Cycle Check (Week 6)

Repeat the CBC with differential and hsCRP. A meaningful immune response typically shows a 15 to 25 percent rise in absolute CD8+ count and a shift in hsCRP toward the <1.0 mg/L optimal range if baseline was elevated. If no measurable shift occurs by week 6, reassess peptide source quality and storage conditions before extending the cycle.

End-of-Cycle Panel (Week 12 to 14)

Repeat the full baseline panel two weeks after the last injection. Compare CD4/CD8 ratio and NK cell activity against baseline. In the hepatitis B RCT population, statistically significant T-cell changes were measurable at 8 weeks of twice-weekly dosing [4]. Longevity users should expect subtler shifts, given that the starting immune dysfunction in a healthy 40-year-old is less severe than in a hepatitis B patient.

Expected Timeline of Outcomes

Outcomes from TA-1 are not acute. Users who expect subjective changes within the first two weeks are likely experiencing placebo effect. The realistic timeline based on the clinical literature:

Weeks 1 to 4: No subjective change in most users. Subclinical immune priming is occurring at the cellular level. Possible mild fatigue on injection days in a minority of users.

Weeks 5 to 8: The hepatitis B trial data suggest NK cell activity peaks in this window [4]. Some users report reduced frequency or severity of routine viral illnesses (common cold, oral herpes reactivation). Lab markers may begin to shift.

Weeks 9 to 12: The most frequently reported subjective outcomes in observational practitioner case series include improved recovery from exercise, reduced frequency of illness, and subjective improvements in energy and mood. These are difficult to attribute specifically to TA-1 versus concurrent lifestyle optimization common in biohacking cohorts.

Months 3 to 6 (post-cycle): In the hepatitis B population, virologic and immunologic responses continued improving for 6 months post-treatment [4]. Whether this durability applies to healthy-aging immune calibration is extrapolated, not proven.

Safety Profile and Contraindications

TA-1 has an unusually clean safety record for a biologically active peptide. In the sepsis trial (N=361), adverse event rates did not differ significantly between TA-1 and placebo groups [5]. The hepatitis B trial reported mild injection-site reactions in 12 percent of the TA-1 group versus 8 percent of controls [4]. No hepatotoxicity, nephrotoxicity, or serious immune-mediated adverse events were reported in either trial.

Who Should Not Use TA-1

• Individuals with active autoimmune conditions (rheumatoid arthritis, lupus, multiple sclerosis). TA-1 increases Th1 activity, which may worsen conditions driven by Th1 excess.
• Organ transplant recipients on immunosuppressants. Enhanced T-cell activity could accelerate rejection.
• Anyone taking systemic corticosteroids or other immunosuppressive drugs. Pharmacodynamic antagonism negates TA-1's mechanism and may produce unpredictable immune shifts.
• Pregnant or breastfeeding individuals. No safety data exist.

A Note on Sourcing

TA-1 is not FDA-approved in the United States. It is approved in over 35 countries under the brand name Zadaxin (SciClone Pharmaceuticals) for chronic hepatitis B. In the U.S., it is available only through compounding pharmacies as a research compound or via international pharmacy. The FDA has not issued a specific enforcement action against compounded TA-1 as of the date of this article, but regulatory status can change. Always verify your source uses third-party mass spectrometry verification and endotoxin (LAL) testing [11].

Regulatory and Ethical Considerations

The Endocrine Society's 2019 position statement on compounded bioidentical hormones and peptides notes that peptides produced outside FDA-approved manufacturing pathways may vary substantially in purity and potency [12]. The same caution applies to TA-1. Contamination with bacterial endotoxin is the primary safety concern with improperly produced peptides, and endotoxin-contaminated injections can trigger severe febrile reactions and systemic inflammation, the opposite of the intended effect.

Practitioners in the longevity medicine space, including those referenced in community protocols attributed to figures like Peter Attia or Andrew Huberman's extended networks, consistently emphasize that no public figure has formally endorsed a specific TA-1 protocol in peer-reviewed or public clinical commentary. Users attributing protocols to named influencers should verify those claims against primary sources.